Mst (Morphine Sulfate)

Morphine sulfate, the active ingredient in Mst, is an opioid analgesic presented as an oral formulation for oral use. It provides analgesia for severe acute pain, chronic cancer pain, and postoperative pain in adult patients requiring strong pain control, and is commonly prescribed under carefully controlled medical supervision.

GNH USA supplies Mst as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Morphine sulfate is an opioid analgesic used to manage severe pain conditions.

- Severe acute pain: delivers rapid, potent analgesia to reduce intense, sudden pain episodes in emergency or trauma settings. - Chronic cancer pain: provides sustained opioid effect to alleviate persistent malignant disease‑related pain, improving quality of life for oncology patients. - Postoperative pain: controls pain after surgical procedures, enabling early mobilization and reducing reliance on additional analgesics. - Severe burn pain: offers strong analgesic effect to manage intense pain from extensive thermal injuries.

Morphine sulfate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: feeling of sickness that may lead to vomiting. - Constipation: reduced bowel movements and hard stools. - Drowsiness: increased sleepiness or fatigue. - Dry mouth: reduced salivation causing throat discomfort.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - Severe allergic reaction: rash, swelling, bronchospasm, or anaphylaxis.

When prescribing morphine sulfate, clinicians should consider several safety precautions to minimize risks. - Assess pain severity and opioid tolerance: evaluate patient’s pain level and prior opioid exposure before initiating therapy. - Monitor respiratory function: observe for signs of respiratory depression, especially during dose titration or in high‑risk patients. - Evaluate for contraindications: avoid use in patients with known hypersensitivity to opioids or significant respiratory disease. - Use lowest effective dose: start with the minimal dose required for analgesia and adjust cautiously. - Educate patient on dependence risk: inform about potential for addiction, tolerance, and withdrawal symptoms. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Morphine sulfate can interact with other medicines, altering its effect or increasing adverse reactions.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, barbiturates): may cause profound sedation and respiratory depression. - MAO inhibitors: can precipitate severe hypotension or serotonin syndrome. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase morphine plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce morphine effectiveness. - Anticholinergics: can worsen constipation. - Diuretics: may enhance hypotensive effects.